Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients
Calara PS, Althin R, Steen Carlsson K & Schmitt-Egenolf M
Observational studies suggest an inequitable prescription of biologics in psoriasis care, which may be attributed to geographical differences in treatment access. Sweden regularly ranks high in international comparisons of equitable healthcare, and is, in connection with established national registries, an ideal country to investigate potential inequitable access. The aim was to determine whether the opportunity for patients to receive biologics depends on where they receive care.
Biologic-naïve patients enrolled in the Swedish National Register for Systemic Treatment of Psoriasis (PsoReg) from 2008 to 2015 (n = 4168) were included. The association between the likelihood of initiating a biologic and the region where patients received care was analyzed. The strength of the association was adjusted for patient and clinical characteristics, as well as disease severity using logistic regression analysis. The proportion of patients that switched to a biologic (switch rate) and the probability of switch to a biologic was calculated in 2-year periods.
The national switch rate increased marginally over time from 9.7 to 11.0%, though the uptake varied across regions. Adjusted odds ratios for at least one region were significantly different from the reference region in every 2-year period. During the latest period (2014–2015), the average patient in the lowest prescribing region was nearly 2.5 times less likely to switch as a similar patient in the highest prescribing region.
Geographical differences in biologics prescription persist after adjusting for patient characteristics and disease severity. The Swedish example calls for further improvements in delivering equitable psoriasis care.
Denna studie har uppmärksammats av Dagens Medicin (8 mars) som varit i kontakt med sjukvården för att diskutera studiens resultat.
Studien baserades på data från det nationella kvalitetsregistret för systembehandling vid psoriasis, PsoReg, och visar att det finns regionala skillnader i förskrivning även om man tar hänsyn till patientkaraktäristika och sjukdomssvårighet.
Läs artikel »
(Dagens Medicin nr 10, 2017 sid 12)
BioDrugs, 2017; 31(1): 75-82